| Basics |
PTC Therapeutics, Inc.
PTC Therapeutics Inc is a biopharmaceutical company. It is focused on the discovery and development of orally administered, proprietary small-molecule drugs that target post-transcriptional control processes.
|
| IPO Date: |
June 20, 2013 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$6.2B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.86 | 2.65%
|
| Avg Daily Range (30 D): |
$1.11 | 1.46%
|
| Avg Daily Range (90 D): |
$1.08 | 1.76%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.73M |
| Avg Daily Volume (30 D): |
1.25M |
| Avg Daily Volume (90 D): |
1.11M |
| Trade Size |
| Avg Trade Size (Sh.): |
89 |
| Avg Trade Size (Sh.) (30 D): |
56 |
| Avg Trade Size (Sh.) (90 D): |
52 |
| Institutional Trades |
| Total Inst.Trades: |
7,436 |
| Avg Inst. Trade: |
$2.69M |
| Avg Inst. Trade (30 D): |
$10.48M |
| Avg Inst. Trade (90 D): |
$7.1M |
| Avg Inst. Trade Volume: |
.06M |
| Avg Inst. Trades (Per Day): |
2 |
| Market Closing Trades |
| Avg Closing Trade: |
$4.48M |
| Avg Closing Trade (30 D): |
$36.78M |
| Avg Closing Trade (90 D): |
$20.3M |
| Avg Closing Volume: |
108.18K |
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
|
$.2
|
$-.83
|
|
Diluted EPS
|
|
$.2
|
$-.83
|
|
Revenue
|
$
|
$ 211.01M
|
$ 178.88M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$
|
$ 15.9M
|
$ -64.85M
|
|
Operating Income / Loss
|
$
|
$ 3.02M
|
$ -34.96M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$
|
$ -340.71M
|
$ -476.38M
|
|
PE Ratio
|
|
|
|
|
|
|
